SOLICITATION NOTICE
66 -- Supplies for government-owned Illumina Genome Analyzer/ Whole-Genome DASL Assay for government-owned Illumina BeadArray Reader
- Notice Date
- 8/13/2009
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90183-AV
- Archive Date
- 9/8/2009
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Genetics Branch plans to procure on a sole source basis with Illumina, Inc, 9885 Towne Center Drive, San Diego, California 92121, supplies for government-owned Illumina Genome Analyzer (NIH #01738254, s/n 300204) and Whole-Genome DASL Assay for government-owned Illumina BeadArray Reader (NIH # 01558759, s/n S149). The supplies are herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106-(b) (1). The North American Industry Classification System Code is 325413 and the business size standard is 500 employees. Delivery date: two weeks from date of award. The government-owned Illumina Genome Analyzer (NIH #01738254, Ser. #300204), located in the Genetics Branch, NCI, is a massively parallel next-generation sequencing by synthesis instrument. It has become a core technology for genome analysis and discovery in the laboratory as is related to the biology of cancer. The supplies for the Illumina Genome Analyzer will allow the lab to continue to generate sequence data relevant to research on the existing instrument. The Illumina Whole Genome DASL assay gene expression platform is designed to work with the existing government-owned Illumina Bead Array Reader (NIH #01558759, Ser. #S149) for investigation of expression profiles in degraded samples such as formalin fixed paraffin embedded tissues (FFPE). FFPE tissues are a particularly challenging yet an informatically rich target for investigation. Illumina Whole Genome DASL expression beadchips are a unique approach to addressing reproducibility and quality issues in microarray data. Each beadtype or target is presented as 30-40 replicate beads. By hybridizing to replicate targets, the lab can average data, to provide reproducibility and quality not possible through any other vendor. Further, due to the high density of the micro-beads, multiple arrays (8) are manufactured on a single slide allowing multiple consecutive experiments to be performed, reducing labor and reagent supply. Illumina Solexa Genome Analyzer Reagents and Whole-Genome DASL Assay are specifically designed for both the existing Illumina Genome Analyzer (NIH #01738254, Ser. #300204) and Illumina BeadArray Reader (NIH #01558759, Ser. #S149) currently in use in the Genetics Branch, NCI. Illumina is the sole source manufacturer of the Genome Analyzer and BeadArray Reader and the reagents appropriate for use on the instrumentation. The reagent content related to the Genome Analyzer and BeadArray Reader is proprietary and protected under patent rights and thereby is unavailable from other sources. Use of reagents on these instruments from other sources would void support of the assays by Illumina; accordingly, Illumina is the only source known to the government capable of providing these supplies. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can meet this requirement. One (1) original and one (1) copy of the capability statement must be received in the contracting office by 1:00 p.m. ET on August 24, 2009. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to Ashley Virts: virtsa@mail.nih.gov. It is the vendor's responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must have valid, updated registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Application (ORCA). Please reference NCI-90183-AV on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90183-AV/listing.html)
- Record
- SN01910664-W 20090815/090814000316-b0370c08899b80f393e3aef1835f5907 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |